Eagle Capital Growth Stock Quote GRF - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

9.40

Bid

Ask

Volume

13,083

9.26 Day's Range 9.48

7.93 52 Week Range 10.19

Market Cap

37.298M

Previous Close

9.48

Open

9.48

Last Trade

100

9.4

Last Trade Time

Financial Volume

$ 122,128

VWAP

9.3349

Average Volume (3m)

2,088

Shares Outstanding

3,967,836

Dividend Yield

3.72%

PE Ratio

8.09

Earnings Per Share (EPS)

1.16

Revenue

736k

Net Profit

4.61M

The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments.

Sector

Unit Inv Tr, Closed-end Mgmt

Industry

Unit Inv Tr, Closed-end Mgmt

Headquarters

Lutherville Timonium, Maryland, USA

Founded

1970

Eagle Capital Growth Fund Inc is listed in the Unit Inv Tr, Closed-end Mgmt sector of the American Stock Exchange with ticker GRF. The last closing price for Eagle Capital Growth was $9.48. Over the last year, Eagle Capital Growth shares have traded in a share price range of $ 7.93 to $ 10.19.

Eagle Capital Growth currently has 3,967,836 shares outstanding. The market capitalization of Eagle Capital Growth is $37.62 million. Eagle Capital Growth has a price to earnings ratio (PE ratio) of 8.09.

Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years

Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S...

Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group

With today’s announcement of the transaction completion, Grifols and Haier Group will work together through Shanghai RAAS (SRAAS) to drive synergies that enhance China’s healthcare systemThrough a...

Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies

With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous immunoglobulins to meet strong demand Yimmugo, already approved for production and...

Form 4 - Statement of changes in beneficial ownership of securities

Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.

The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.02	-0.212314225053	9.42	9.5	9.26	2641	9.37829231	CS
4	0.39	4.32852386238	9.01	9.55	9.01	2839	9.34762983	CS
12	-0.04	-0.423728813559	9.44	9.93	8.9	2088	9.33560454	CS
26	0.375	4.15512465374	9.025	9.93	8.78	2703	9.29948251	CS
52	0.62	7.06150341686	8.78	10.19	7.93	3081	9.03046811	CS
156	0.25	2.73224043716	9.15	11.25	7.8	4678	9.08158123	CS
260	1.3	16.049382716	8.1	11.25	5.2	4857	8.37752811	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WINTWindtree Therapeutics Inc	$ 8.24 (150.46%)	48.57M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NBSTWNewbury Street Acquisition Corporation	$ 0.1349 (92.71%)	122.1k
YIBOPlanet Image International Ltd	$ 2.915 (53.43%)	260.07k
CREVCarbon Revolution Public Ltd	$ 9.00 (45.87%)	8.06M
NMHINatures Miracle Holding Inc	$ 0.2035 (-48.06%)	7.69M
TANHTantech Holdings Ltd	$ 0.2585 (-47.23%)	6.75M
DXCMDexCom Inc	$ 64.00 (-40.66%)	53.92M
PSIGPS International Group Ltd	$ 1.42 (-31.40%)	716.26k
POAIPredictive Oncology Inc	$ 1.36 (-27.27%)	6.02M
SLNASelina Hospitality PLC	$ 0.0305 (-18.88%)	408.61M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NVDANVIDIA Corporation	$ 113.06 (0.69%)	293.33M
SQQQProShares UltraPro Short QQQ	$ 9.10 (-2.88%)	176.49M
SGMOSangamo Therapeutics Inc	$ 0.8612 (28.15%)	123.71M